Entering text into the input field will update the search result below

Enrollment underway in Cardiovascular Systems' late-stage study of Diamondback atherectomy device compared to angioplasty

Mar. 28, 2017 4:03 PM ETAbbott Laboratories (ABT) StockBy: Douglas W. House, SA News Editor1 Comment
  • The first patient has been enrolled in a clinical trial, ECLIPSE, assessing Cardiovascular Systems' (NASDAQ:CSII +0.3%) Diamondback 360 Coronary Orbital Atherectomy System in patients with severely calcified coronary arteries.
  • The prospective study will enroll ~2,000 subjects with half receiving orbital atherectomy prior to drug-eluting stent (DES) implantation and the other half conventional angioplasty before receiving a DES.
  • The FDA approved the Diamondback 360 in October 2013.

Recommended For You

About ABT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABT--
Abbott Laboratories